BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 23, 2009
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 4Q08 EPS est 4Q08 EPS actual Outcome Growth from 4Q07 2/20cls Wk chg % chg Mcap chg 2/20 Mcap
Actelion (SWX:ATLN) NA CHF0.67 NA 6% CHF 60.00 -CHF 2.90 -5% -$333.5 $6,397.5
Sales of Tracleer bosentan for pulmonary arterial hypertension (PAH) were CHF348.3M ($326.3M), up from CHF332M in 4Q07. Fourth quarter revenues came in at CHF403.9M, compared with CHF370.9M in 4Q07. Fourth quarter operating expenses rose 15% to CHF307.7M from CHF268.8M in the same period in 2007.
BioMarin (NASDAQ:BMRN) $0.26 $0.21 Missed by $0.05 600% $11.81 -$6.75 ...

Read the full 728 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >